Lung Cancer

John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, discusses a study on KRAS mutations in lung cancer, which led to the identification of three more KRAS subsets.

Treatment with AZD9291 at 80 mg per day elicited a response in 66% of patients with EGFR T790M-positive non–small cell lung cancer.

Nivolumab (Opdivo) improved survival versus docetaxel in patients with pretreated nonsquamous non–small cell lung cancer in the phase III CheckMate-057 trial.

Brigatinib, an investigational ALK tyrosine kinase inhibitor, demonstrated significant intracranial antitumor activity in patients with ALK-positive non–small cell lung cancer and brain metastases.

Tracey L. Evans, MD, associate professor of clinical medicine, University of Pennsylvania Health System, discusses treatment of poor performance status (PS) and elderly patients with lung cancer.

Thomas Lynch, who is director of the Yale Cancer Center and physician-in-chief at the Smilow Cancer Hospital at Yale-New Haven, recently sat down with OncLive and discussed key strategies and trends in the management of lung cancer.

James P. Stevenson, MD, discusses optimization of drug and patient selection for maintenance therapies in NSCLC, and how it will continue to be a research focus in today's environment of value-based care.

Eligibility criteria set by the Centers for Medicare & Medicaid Services for coverage of low-dose computed tomography for individuals deemed at high risk for lung cancer may actually exclude many potential lung cancer patients who would benefit from screening.

Thomas J. Lynch, MD, director, Yale Cancer Center, physician-in-chief, Smilow Cancer Hospital at Yale-New Haven, Giant of Lung Cancer Care, discusses expanding the number of molecular subsets in non-small cell lung cancer (NSCLC).

Increasing the minimum age of legal access (MLA) to tobacco products will prevent or delay initiation of tobacco use by adolescents and young adults, particularly those ages 15 to 17, and improve the health of Americans across the lifespan.

Prior cancer history should not exclude patients with advanced lung cancer from participating in clinical trials because it does not impact clinical outcomes.

OncLive sat down with Edward Kim, MD, to learn more about the impact of recent advances in NSCLC and what the future treatment paradigm might look like.

Acting 3 months ahead of schedule, the FDA approved nivolumab (Odivo) for patients with squamous non-small cell lung cancer.

The FDA has granted a priority review to nivolumab for use in patients with previously treated, advanced, squamous non–small cell lung cancer.